Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 1

Conditions

Carcinoma, Hepatocellular 63Colorectal Neoplasms 30Biliary Tract Neoplasms 29Cholangiocarcinoma 27Pancreatic Neoplasms 26Liver Neoplasms 18Stomach Neoplasms 13Esophageal Neoplasms 11Carcinoma, Non-Small-Cell Lung 11Breast Neoplasms 10Gallbladder Neoplasms 9Adenocarcinoma Of Esophagus 9Neoplasm Metastasis 8Esophageal Squamous Cell Carcinoma 8Ovarian Neoplasms 7Melanoma 7Squamous Cell Carcinoma of Head and Neck 6Small Cell Lung Carcinoma 6Carcinoma, Renal Cell 6Carcinoma 6Bile Duct Neoplasms 6Triple Negative Breast Neoplasms 5Rectal Neoplasms 5Prostatic Neoplasms 5Colonic Neoplasms 5Uterine Cervical Neoplasms 4Lung Neoplasms 4Diabetes Mellitus, Insulin-Dependent, 12 4Adenocarcinoma 4Neoplasms 3

Interventions

Oxaliplatin 30Gemcitabine 28Fluorouracil 27Capecitabine 22Leucovorin 19pembrolizumab 15130-nm albumin-bound paclitaxel 13Irinotecan 12Cisplatin 11Bevacizumab 11Albumin-Bound Paclitaxel 11Paclitaxel 10Ramucirumab 8Radiotherapy 8Docetaxel 8Nivolumab 7trastuzumab deruxtecan 6Cyclophosphamide 6Taxes 5Drug Therapy 5durvalumab 4Trastuzumab 4Metformin 4zolbetuximab 3spartalizumab 3folfirinox 3cemiplimab 3XELOX 3Surgical Procedures, Operative 3Sorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Adenocarcinoma × durvalumab × Gastrointestinal × Clear all
NCT05063565 2026-06-01

ROWAN

Boston Scientific Corporation

Phase 2 Active not recruiting
100 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

NCT04379596 2026-05-13

DG-03

AstraZeneca

Phase 2 Recruiting
450 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT05620628 2026-01-21

Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)

Samsung Medical Center

Phase 2 Recruiting
25 enrolled
Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT03777813 2025-11-18

ARION

UNICANCER

Phase 2 Completed
112 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡